Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Fig. 3

XPO1 inhibitor KPT-335 induces nuclear accumulation of FOXO1 and RB1 through inhibiting PI3K/AKT pathway. A Heatmap and Go function analysis, B KEGG pathway, C GSEA analysis of differential genes (|Log2FC|≥ 1.6, P < 0.001) of SK-N-BE(2) after KPT-335 treatment. D Western blot analysis of FOXO1 and Rb1 levels in nucleus and cytoplasm of SK-N-BE(2) after KPT-335 treatment. E knockdown of FOXO1 and RB1 attenuated effective of KPT-335 in SK-N-BE(2). F Western blot analysis of FOXO1 and RB1 levels in nucleus and cytoplasm of SH-SY5Y after KPT-335 treatment. G Knockdown of FOXO1 and RB1 attenuated inhibition effects of KPT-335 in SH-SY5Y. H XPO1, p-PI3K, PI3K, p-AKT, AKT, p-FOXO1, p-RB1 expression levels detected by western blotting. I 740 Y-P attenuated inhibition effects of KPT-335 in SK-N-BE(2) and SH-SY5Y. Data presented as mean ± SD (n = 3). ** P < 0.01, *** P < 0.001

Back to article page